drugset / Trial / NCT00246467
One Year Study to Evaluate Three Different Adjuvanted Doses of the Recombinant Plague Vaccine (rF1 and rV Antigens)
Phase 1
Completed
123 enrolled
PharmAthene UK Limited
National Institute of Allergy and Infectious Diseases (NIAID) · collab
RandomizedParallel-groupSingle-blindPrevention
Summary
One hundred and five subjects will be recruited into three groups. Each subject will receive two doses of recombinant plague vaccine at one of three dose levels (rF1 and rV recombinant antigen proteins).
Timeline
- Start
- 2005-10
- Primary completion
- 2007-04
- Completion
- 2007-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | rF1 | Protein / enzyme biologic | — | Intramuscular |
| Subject | rV | Protein / enzyme biologic | — | Intramuscular |
| Background | Aluminum hydroxide | Unknown | — | — |